Form 4: MoonLake Immunotherapeutics Director Acquires Options
SEC Form 4
Director Ramnik Xavier acquired options to purchase 7,688 Class A Ordinary Shares in MoonLake Immunotherapeutics on June 6, 2024.
Summary
- On June 6, 2024, Ramnik Xavier, a director of MoonLake Immunotherapeutics, acquired options to purchase 7,688 Class A Ordinary Shares.
- The exercise price of the options is $42.44.
- The options vest in full on the earlier of June 6, 2025, the date of the Issuer's next annual general meeting of shareholders, or the date of a Change in Control of the Issuer, subject to continued service.
- The options expire on June 6, 2034.
Sentiment
Score: 5
Explanation: This is a routine transaction; the sentiment is neutral.
Industry Context
This is a standard Form 4 filing, reflecting a director's acquisition of options, which is a common form of executive compensation in the biotechnology industry.
Stakeholder Impact
- The acquisition of options by a director could be seen as a positive sign by shareholders, indicating confidence in the company's future performance.
Key Dates
| Date | Description |
|---|---|
| 06/06/2024 | Date of the option grant. |
| 06/06/2025 | Earliest vesting date of the options. |
| 06/06/2034 | Expiration date of the options. |
| 06/07/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.